Literature DB >> 26490357

A limited sampling strategy based on maximum a posteriori Bayesian estimation for a five-probe phenotyping cocktail.

Thu Thuy Nguyen, Henri Bénech, Alain Pruvost, Natacha Lenuzza.   

Abstract

PURPOSE: Cocktail approach using a combination of probes to phenotype several cytochromes P450 or transporters is of high interest in anticipating drug–drug interactions and personalized medicine. Its clinical use remains however limited by the intensive sampling scheme required to obtain phenotyping indexes (PI) which consists in calculating the area under the concentration–time curves. We proposed to use maximum a posteriori Bayesian estimation (MAPBE) that incorporates available information from the whole population to derive PI from a few individual observations. The performance of a limited sampling strategy (LSS) based on MAPBE was evaluated for a five-probe cocktail.
METHODS: The studied cocktail included midazolam, tolbutamide, caffeine, dextromethorphan, omeprazole and their relevant metabolites. Prior information for MAPBE was obtained by nonlinear mixed-effect modelling of data from a pilot study. Sampling times were chosen based on optimal design theory using the Bayesian Fisher information matrix. Through a simulation study, we investigated the predicted PI in terms of bias and imprecision for varying number and timing of samples.
RESULTS: Some three-point Bayesian designs gave mean prediction errors in [−5 %, 5 %], root mean square errors below 30 % for all probes, except dextromethorphan whose model should be consolidated further with additional data. This approach gave overall less outlier predicted values than single-point metrics and was more flexible to the timing of the latest sampling.
CONCLUSIONS: MAPBE is accurate for predicting simultaneously several PI while being flexible in terms of integrating clinical constraints. Therefore, LSS based on MAPBE could help reduce the time of presence in hospital for individuals to be phenotyped.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26490357     DOI: 10.1007/s00228-015-1953-5

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  39 in total

1.  Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotype-phenotype relationship in Swedes and Koreans.

Authors:  Roza Ghotbi; Magnus Christensen; Hyung-Keun Roh; Magnus Ingelman-Sundberg; Eleni Aklillu; Leif Bertilsson
Journal:  Eur J Clin Pharmacol       Date:  2007-03-17       Impact factor: 2.953

2.  Design evaluation and optimisation in multiple response nonlinear mixed effect models: PFIM 3.0.

Authors:  Caroline Bazzoli; Sylvie Retout; France Mentré
Journal:  Comput Methods Programs Biomed       Date:  2009-11-04       Impact factor: 5.428

3.  Safety and pharmacokinetics of the CIME combination of drugs and their metabolites after a single oral dosing in healthy volunteers.

Authors:  Natacha Lenuzza; Xavier Duval; Grégory Nicolas; Etienne Thévenot; Sylvie Job; Orianne Videau; Céline Narjoz; Marie-Anne Loriot; Philippe Beaune; Laurent Becquemont; France Mentré; Christian Funck-Brentano; Loubna Alavoine; Philippe Arnaud; Marcel Delaforge; Henri Bénech
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-12-03       Impact factor: 2.441

4.  Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients.

Authors:  Sweta Tandra; Naga Chalasani; David R Jones; Samer Mattar; Stephen D Hall; Raj Vuppalanchi
Journal:  Ann Surg       Date:  2013-08       Impact factor: 12.969

5.  Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.

Authors:  Ron H J Mathijssen; Floris A de Jong; Ron H N van Schaik; Erin R Lepper; Lena E Friberg; Trinet Rietveld; Peter de Bruijn; Wilfried J Graveland; William D Figg; Jaap Verweij; Alex Sparreboom
Journal:  J Natl Cancer Inst       Date:  2004-11-03       Impact factor: 13.506

6.  Correlation of cytochrome P450 (CYP) 1A2 activity using caffeine phenotyping and olanzapine disposition in healthy volunteers.

Authors:  Kara Lee Shirley; Yuen Y Hon; Scott R Penzak; Y W Francis Lam; Vicky Spratlin; Michael W Jann
Journal:  Neuropsychopharmacology       Date:  2003-03-19       Impact factor: 7.853

7.  The basel cocktail for simultaneous phenotyping of human cytochrome P450 isoforms in plasma, saliva and dried blood spots.

Authors:  Massimiliano Donzelli; Adrian Derungs; Maria-Giovanna Serratore; Christoph Noppen; Lana Nezic; Stephan Krähenbühl; Manuel Haschke
Journal:  Clin Pharmacokinet       Date:  2014-03       Impact factor: 6.447

8.  Pharmacokinetics of dextromethorphan and dextrorphan: a single dose comparison of three preparations in human volunteers.

Authors:  M Silvasti; P Karttunen; H Tukiainen; P Kokkonen; U Hänninen; S Nykänen
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1987-09

9.  CPT: Pharmacometrics and Systems Pharmacology.

Authors:  Piet H van der Graaf
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2012-09-26

10.  Current Use and Developments Needed for Optimal Design in Pharmacometrics: A Study Performed Among DDMoRe's European Federation of Pharmaceutical Industries and Associations Members.

Authors:  F Mentré; M Chenel; E Comets; J Grevel; A Hooker; M O Karlsson; M Lavielle; I Gueorguieva
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-06-05
View more
  2 in total

1.  Evaluation of Omeprazole Limited Sampling Strategies to Estimate Constitutive Cytochrome P450 2C19 Activity in Healthy Adults.

Authors:  Swan Lin; Mina Nikanjam; Edmund V Capparelli; Alessandro Allegrini; Daniele Pavone; Dong-Seok Yim; Muhammad M Hammami; Joseph S Bertino; Anne N Nafziger; Yoo-Sin Park; Ju-Seop Kang; Ophelia Q Yin; Joseph D Ma
Journal:  Ther Drug Monit       Date:  2018-12       Impact factor: 3.681

2.  Use of Mixture Dosing and Nonlinear Mixed Effect Modeling of Eight Environmental Contaminants in Rabbits to Improve Extrapolation Value of Toxicokinetic Data.

Authors:  Véronique Gayrard; Jessika Moreau; Nicole Picard-Hagen; Virginie Helies; Philippe Marchand; Jean-Philippe Antignac; Pierre-Louis Toutain; Roger Leandri
Journal:  Environ Health Perspect       Date:  2021-11-17       Impact factor: 9.031

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.